Flualprazolam
Triazolobenzodiazepine drug From Wikipedia, the free encyclopedia
Flualprazolam is a tranquilizer of the triazolobenzodiazepine (TBZD) class, which are benzodiazepines (BZDs) fused with a triazole ring. It was first synthesised in 1976,[2] but was never marketed. It can be seen as the triazolo version of fludiazepam. It has subsequently been sold as a designer drug,[3][4][5][6] first being definitively identified as such in Sweden in 2018.[7][8] It can be described as the 2'-fluoro derivative of alprazolam or the fluoro instead of chloro analogue of triazolam, and has similar sedative and anxiolytic effects.[9][10][11][12][13]
| |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H12ClFN4 |
| Molar mass | 326.76 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Legal status
Flualprazolam is banned in Sweden, also is illegal in the UK.[14] In December 2019, the World Health Organization recommended flualprazolam for international scheduling as a Schedule IV medication under the Convention on Psychotropic Substances.[15]
In the United States, Oregon and Virginia have placed Flualprazolam into Schedule I.[16] On December 23, 2022, the DEA announced it had begun consideration on the matter of placing Flualprazolam under temporary Schedule I status.[17] Later on July 25, 2023, the DEA published a pre-print notice that Flualprazolam would become temporarily scheduled as a Schedule I controlled substance from 26 July 2023 to 26 July 2025.[18]
See also
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.